Ocular Therapeutix Expands Team With Inducement Grant
Ocular Therapeutix, Inc. (NASDAQ: OCUL), a passionate biopharmaceutical company focused on redefining the retina experience, has recently announced a strategic decision to enhance its team. The company has granted inducement awards to a newly hired non-executive employee, reflecting its dedication to attracting top talent in the industry.
Details of the Inducement Awards
The inducement equity awards were confirmed effective as of November 3rd, 2025. These awards comprise a non-statutory stock option that allows the purchase of up to 1,100 shares of Ocular's common stock. Alongside this option, a restricted stock unit award has been included, entitling the recipient to receive 367 shares of common stock. This structure not only incentivizes the new employee but also aligns their interests closely with the company's success.
Stock Option and Vesting Schedule
The stock option stands with an exercise price set at $11.47 per share. This figure is consistent with the closing price of Ocular's shares on the Nasdaq Global Market at the time of the grant. This stock option is designed to vest over four years. The initial 25% of shares will become available on October 20th, 2026, with the remaining shares vesting in equal monthly installments over the subsequent three years, contingent upon the recipient's continued service with the company.
Restricted Stock Unit Vesting
In tandem with the stock option, the restricted stock unit is scheduled to vest over a three-year period in equal annual installments. The first layer of shares will vest on November 3rd, 2026, also dependent on the new employee’s ongoing service to Ocular. This structured vesting schedule is designed to cultivate a long-term commitment between the employee and Ocular, fostering engagement and alignment with the company’s goals.
About Ocular Therapeutix, Inc.
Ocular Therapeutix is at the forefront of biopharmaceutical innovations. Our mission centers around transforming the retinal experience, and we are particularly proud of our investigational product candidate, AXPAXLI™ (OTX-TKI). This novel treatment for retinal diseases uses an axitinib intravitreal hydrogel based on our proprietary ELUTYX™ technology.
Clinical Trials and Product Pipeline
Currently, AXPAXLI is undergoing Phase 3 clinical trials targeting wet age-related macular degeneration (wet AMD). Furthermore, a Phase 3 clinical program for non-proliferative diabetic retinopathy (NPDR) is expected to commence shortly. This commitment to advancing retinal health signifies our ongoing dedication to innovation in the field.
Our product pipeline also includes DEXTENZA®, an FDA-approved corticosteroid indicated for treating ocular inflammation and pain after ophthalmic surgeries. This treatment is available to both adults and pediatric patients. Additionally, we are advancing our investigational product candidate, OTX-TIC, a travoprost intracameral hydrogel currently in evaluation following a successful Phase 2 clinical trial targeting open-angle glaucoma and ocular hypertension.
Connect With Us
As we continue to innovate and expand our product offerings, we invite you to explore our recent corporate branding and get to know us better. You can find more information about our initiatives and stay connected with us through our website and social media channels.
Investors & Media Contact
For further inquiries or information, please reach out to Bill Slattery, Vice President of Investor Relations at Ocular Therapeutix, Inc. You can contact him via email: bslattery@ocutx.com.
Frequently Asked Questions
What are inducement awards?
Inducement awards are stock options or shares granted to new employees as an incentive to accept a job offer, aligned with the company's performance.
What is the purpose of the vesting schedule?
The vesting schedule ensures that employees remain engaged with the company over a period, promoting long-term commitment and alignment.
What is AXPAXLI?
AXPAXLI is an investigational treatment for retinal diseases currently undergoing clinical trials, showcasing the company's commitment to advancing eye health.
How does DEXTENZA function?
DEXTENZA is an FDA-approved corticosteroid that treats pain and inflammation after eye surgeries, available for both adults and pediatric patients.
How can I find out more about Ocular Therapeutix?
You can learn more by visiting their official website and following them on their social media platforms for the latest updates and news.
